Zanidatamab + Chemotherapy as First line Treatment for HER2 expressing Metastatic Gastroesophageal Adenocarcinoma (mGEA)
Zanidatamab + Chemotherapy as First line Treatment for HER2 expressing Metastatic Gastroesophageal Adenocarcinoma (mGEA)
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers (BTCs)
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers (BTCs)
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study
